RxDoctor Payments DataLook up a doctor →

Matthew Teltser, MD

Cardiovascular Disease · Davie, FLNPI 1275570020

Payments from drug & device makers

$883,239in general payments, 2019–2025

Across 225 payments — averaging $3925.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$693K
  • Novartis$157K
  • Boehringer Ingelheim Canada Ltd.ltee$13K
  • Chiesi USA, Inc.$10K
  • Boehringer Ingelheim$6K
  • Novo Nordisk AS$1K
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$4,02699%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$883,239 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$71,477
Medicare patients
607
Services billed
1,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$143,554
Repatha SureclickEvolocumab72$69,694
XareltoRivaroxaban79$67,647
EntrestoSacubitril/Valsartan43$51,736
JardianceEmpagliflozin38$47,186
FarxigaDapagliflozin Propanediol39$36,374
Repatha SyringeEvolocumab11$15,390
Praluent PenAlirocumab19$11,277
Eplerenone67$8,728
Telmisartan263$6,235
Ezetimibe329$5,327
LivaloPitavastatin Calcium13$4,183
Atorvastatin Calcium366$3,807
Labetalol Hcl54$3,034
Rosuvastatin Calcium224$2,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$214$143,554126 claims
Johnson & JohnsonXarelto$146$67,64779 claims
NovartisEntresto$157,325$51,73643 claims
Boehringer IngelheimJardiance$6,487$47,18638 claims
AstraZenecaFarxiga$692,809$36,37439 claims
Kowa Pharmaceuticals America, Inc.Livalo$25$4,18313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Davie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →